Literature DB >> 23107633

Predictors of sputum culture conversion among patients treated for multidrug-resistant tuberculosis.

E V Kurbatova1, V M Gammino, J Bayona, M C Becerra, M Danilovitz, D Falzon, I Gelmanova, S Keshavjee, V Leimane, C D Mitnick, M I Quelapio, V Riekstina, A Taylor, P Viiklepp, M Zignol, J P Cegielski.   

Abstract

OBJECTIVE: To identify predictors of initial sputum culture conversion, estimate the usefulness of persistent positive cultures at different time points in predicting treatment failure, and evaluate different definitions of culture conversion for predicting failure among patients with multidrug-resistant tuberculosis (MDR-TB) in five countries, 2000-2004.
METHODS: Predictors of time to conversion were identified using multivariate Cox proportional hazards regression modeling. Receiver operating characteristic curves were plotted to visualize the effect of using different definitions of 'culture conversion' on the balance between sensitivity and specificity.
RESULTS: Overall, 1209/1416 (85%) of patients with baseline positive cultures converted in a median of 3.0 months (interquartile range 2.0-5.0). Independent predictors of less likely conversion included baseline positive smear (hazard ratio [HR] 0.60, 95%CI 0.53-0.68), resistance to pyrazinamide (HR 0.82, 95%CI 0.70-0.96), fluoroquinolones (FQs; HR 0.65, 95%CI 0.51-0.83) or thioamide (HR 0.83, 95%CI 0.71-0.96), previous use of FQs (HR 0.71, 95%CI 0.60-0.83), poor outcome of previous anti-tuberculosis treatment (HR 0.69, 95%CI 0.54-0.88) and alcoholism (HR 0.74, 95%CI 0.63-0.87). The maximum combined sensitivity (84%) and specificity (94%) in predicting treatment failure was based on lack of culture conversion at month 9 of treatment, assuming conversion is defined as five consecutive negative cultures.
CONCLUSION: Patients with identified risk factors were less likely to achieve sputum culture conversion during MDR-TB treatment.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23107633     DOI: 10.5588/ijtld.11.0811

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  34 in total

1.  Time for culture conversion and its associated factors in multidrug-resistant tuberculosis patients at a tertiary level hospital in Peshawar, Pakistan.

Authors:  Zafar Iqbal; Mazhar Ali Khan; Aamir Aziz; Syed Muhammad Nasir
Journal:  Pak J Med Sci       Date:  2022 Mar-Apr       Impact factor: 2.340

Review 2.  Tuberculosis Treatment Monitoring and Outcome Measures: New Interest and New Strategies.

Authors:  Jan Heyckendorf; Sophia B Georghiou; Nicole Frahm; Norbert Heinrich; Irina Kontsevaya; Maja Reimann; David Holtzman; Marjorie Imperial; Daniela M Cirillo; Stephen H Gillespie; Morten Ruhwald
Journal:  Clin Microbiol Rev       Date:  2022-03-21       Impact factor: 50.129

3.  Significant clinical impact of a rapid molecular diagnostic test (Genotype MTBDRplus assay) to detect multidrug-resistant tuberculosis.

Authors:  Maia Kipiani; Veriko Mirtskhulava; Nestani Tukvadze; Matthew Magee; Henry M Blumberg; Russell R Kempker
Journal:  Clin Infect Dis       Date:  2014-08-04       Impact factor: 9.079

4.  High Systemic Exposure of Pyrazinoic Acid Has Limited Antituberculosis Activity in Murine and Rabbit Models of Tuberculosis.

Authors:  Jean-Philippe Lanoix; Rokeya Tasneen; Paul O'Brien; Jansy Sarathy; Hassan Safi; Michael Pinn; David Alland; Véronique Dartois; Eric Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

5.  Radiological signs associated with pulmonary multi-drug resistant tuberculosis: an analysis of published evidences.

Authors:  Yì Xiáng J Wáng; Myung Jin Chung; Aliaksandr Skrahin; Alex Rosenthal; Andrei Gabrielian; Michael Tartakovsky
Journal:  Quant Imaging Med Surg       Date:  2018-03

6.  Time to culture conversion and regimen composition in multidrug-resistant tuberculosis treatment.

Authors:  Dylan B Tierney; Molly F Franke; Mercedes C Becerra; Félix A Alcántara Virú; César A Bonilla; Epifanio Sánchez; Dalia Guerra; Maribel Muñoz; Karim Llaro; Eda Palacios; Lorena Mestanza; Rocío M Hurtado; Jennifer J Furin; Sonya Shin; Carole D Mitnick
Journal:  PLoS One       Date:  2014-09-19       Impact factor: 3.240

7.  Diabetes Reduces the Rate of Sputum Culture Conversion in Patients With Newly Diagnosed Multidrug-Resistant Tuberculosis.

Authors:  Argita D Salindri; Maia Kipiani; Russell R Kempker; Neel R Gandhi; Lasha Darchia; Nestani Tukvadze; Henry M Blumberg; Matthew J Magee
Journal:  Open Forum Infect Dis       Date:  2016-06-16       Impact factor: 3.835

8.  Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies.

Authors:  Ekaterina V Kurbatova; J Peter Cegielski; Christian Lienhardt; Rattanawadee Akksilp; Jaime Bayona; Mercedes C Becerra; Janice Caoili; Carmen Contreras; Tracy Dalton; Manfred Danilovits; Olga V Demikhova; Julia Ershova; Victoria M Gammino; Irina Gelmanova; Charles M Heilig; Ruwen Jou; Boris Kazennyy; Salmaan Keshavjee; Hee Jin Kim; Kai Kliiman; Charlotte Kvasnovsky; Vaira Leimane; Carole D Mitnick; Imelda Quelapio; Vija Riekstina; Sarah E Smith; Thelma Tupasi; Martie van der Walt; Irina A Vasilyeva; Laura E Via; Piret Viiklepp; Grigory Volchenkov; Allison Taylor Walker; Melanie Wolfgang; Martin Yagui; Matteo Zignol
Journal:  Lancet Respir Med       Date:  2015-02-26       Impact factor: 30.700

9.  Predictors of two months culture conversion in multidrug-resistant tuberculosis: findings from a retrospective cohort study.

Authors:  Anila Basit; Nafees Ahmad; Amer Hayat Khan; Arshad Javaid; Syed Azhar Syed Sulaiman; Afsar Khan Afridi; Azreen Syazril Adnan; Israr ul Haq; Syed Saleem Shah; Ahmed Ahadi; Izaz Ahmad
Journal:  PLoS One       Date:  2014-04-04       Impact factor: 3.240

10.  Diabetes mellitus, smoking status, and rate of sputum culture conversion in patients with multidrug-resistant tuberculosis: a cohort study from the country of Georgia.

Authors:  Matthew J Magee; Russell R Kempker; Maia Kipiani; Nestani Tukvadze; Penelope P Howards; K M Venkat Narayan; Henry M Blumberg
Journal:  PLoS One       Date:  2014-04-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.